Anti-tumour therapy in paraneoplastic neurological disease

Grisold, Wolfgang; Drlicek, M.; Liszka-Setinek, Ulrike; Wondrusch, E.

doi:10.1016/0303-8467(95)00003-3

Cited by 47 publications

(21 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Steroid pulse therapy was administered with the aim of reducing the spinal cord edema and relieving the neural symptoms that were caused by the myelitis. The early detection of PNS and the treatment of the tumor(s) have a reportedly greater impact on the neurological outcome (14,15) than the use of immunosuppressive therapies (16). The clinical course of this patient was highly consistent with the diagnosis of PNS.…”

Section: Discussionmentioning

confidence: 99%

Paraneoplastic Neurological Syndrome in a Patient with Squamous Cell Lung Cancer

Mori¹,

Yamada²,

Ohno

et al. 2013

Intern. Med.

View full text Add to dashboard Cite

A 78-year-old man presented with urinary retention and difficulty walking. Both legs showed muscle weakness, and he was experiencing lower body hypoesthesia. T2-weighted magnetic resonance imaging revealed lesions with high signal intensity and enhancement in the spinal cord and cerebrum. A cerebrospinal fluid specimen showed inflammatory changes, but negative cytology findings. Chest computed tomography revealed a tumor measuring 40 mm in diameter, and a lung biopsy revealed the presence of squamous cell carcinoma. We diagnosed the patient with paraneoplastic neurological syndrome related to lung cancer. The patient was treated with steroid pulse therapy and chemotherapy, which relieved the symptoms and enabled the patient to achieve an independent gait.

show abstract

Section: Discussionmentioning

confidence: 99%

Paraneoplastic Neurological Syndrome in a Patient with Squamous Cell Lung Cancer

Mori¹,

Yamada²,

Ohno

et al. 2013

Intern. Med.

View full text Add to dashboard Cite

show abstract

“…Only 7 of 134 patients with PCD responded to oncological treatment in a study by Grisold et al [7]. Somewhat in contrast, a recent study showed that patients with PCD receiving antitumour treatment survived significantly longer than untreated patients [13].…”

mentioning

confidence: 90%

Strategies in detection of the primary tumour in anti-Yo associated paraneoplastic cerebellar degeneration

et al. 2005

View full text Add to dashboard Cite

In patients with anti-Yo associated paraneoplastic cerebellar degeneration (PCD) neurological symptoms precede the diagnosis of the underlying cancer in about 60%. Ovarian carcinoma, breast cancer and other gynaecological malignancies are most frequently found as causative malignancies. Antitumour treatment should be applied in an early stage of disease. The identification of the tumour is a diagnostic challenge in many of these patients. In the first of two patients reported here a pelvic tumour was suggested after detection of a pathological lymph node and elevated tumour markers. The intraoperative findings appeared macroscopically normal during ovariectomy with adnexectomy. Not until microscopic examination of the resected tissue was performed was a tubal adenocarcinoma found. If intrapelvic gynaecological tumours are suspected a deliberate surgical exploration seems to be justified, but only after an intensive diagnostic investigation. To search for the underlying cancer in patients with paraneoplastic neurological disorders successive CT and [18F]-FDG-PET are widely recommended. Instead of this in the second reported patient whole-body dual-modality PET/CT was performed revealing enhanced uptake in three regions of the left thorax. By combining function and anatomy PET/CT was able to localise the lesions and characterise them as lymph node metastases of breast cancer. Diagnosis could be confirmed by subsequently executed needle biopsy. PET/CT seems to be highly applicable in the investigation of paraneoplastic disorders with unknown primary cancer. It may help in guidance of needle biopsy or to optimise the results of deliberate surgery and it provides whole-body tumour staging in a single session with higher diagnostic accuracy than PET alone.

show abstract

“…The presence of HuAB at diagnosis of SCLC is thought to be a strong and independent predictor of complete response to treatment and longer survival [3]. However, the improvement of PSN is rarely observed [4].…”

Section: Introductionmentioning

confidence: 99%

A case of spontaneous regression of small cell lung cancer with progression of paraneoplastic sensory neuropathy

et al. 2007

View full text Add to dashboard Cite

Anti-tumour therapy in paraneoplastic neurological disease

Cited by 47 publications

References 47 publications

Paraneoplastic Neurological Syndrome in a Patient with Squamous Cell Lung Cancer

Paraneoplastic Neurological Syndrome in a Patient with Squamous Cell Lung Cancer

Strategies in detection of the primary tumour in anti-Yo associated paraneoplastic cerebellar degeneration

A case of spontaneous regression of small cell lung cancer with progression of paraneoplastic sensory neuropathy

Contact Info

Product

Resources

About